REFERENCES

1. Llovet JM, Kelley RK, Villanueva A, et al. Hepatocellular carcinoma. Nat Rev Dis Primers. 2021;7:6. Erratum in: Nat Rev Dis Primers 2024;10:10.

2. Mak LY, Cruz-Ramón V, Chinchilla-López P, et al. Global epidemiology, prevention, and management of hepatocellular carcinoma. Am Soc Clin Oncol Educ Book. 2018;38:262-79.

3. Shinkawa H, Tanaka S, Kabata D, et al. The prognostic impact of tumor differentiation on recurrence and survival after resection of hepatocellular carcinoma is dependent on tumor size. Liver Cancer. 2021;10:461-72.

4. Saito A, Toyoda H, Kobayashi M, et al. Prediction of early recurrence of hepatocellular carcinoma after resection using digital pathology images assessed by machine learning. Mod Pathol. 2021;34:417-25.

5. Li P, Wu L, Li Z, et al. Spleen radiomics signature: a potential biomarker for prediction of early and late recurrences of hepatocellular carcinoma after resection. Front Oncol. 2021;11:716849.

6. Wang W, Guo Y, Zhong J, et al. The clinical significance of microvascular invasion in the surgical planning and postoperative sequential treatment in hepatocellular carcinoma. Sci Rep. 2021;11:2415.

7. Niu ZS, Niu XJ, Wang WH. Genetic alterations in hepatocellular carcinoma: An update. World J Gastroenterol. 2016;22:9069-95.

8. Su H, Han C, He Y, et al. Molecular mechanism of CK19 involved in the regulation of postoperative recurrence of HBV-associated primary hepatocellular carcinoma in Guangxi. Ann Transl Med. 2021;9:1780.

9. Uenishi T, Kubo S, Yamamoto T, et al. Cytokeratin 19 expression in hepatocellular carcinoma predicts early postoperative recurrence. Cancer Sci. 2003;94:851-7.

10. Zheng Z, Guan R, Jianxi W, et al. Microvascular invasion in hepatocellular carcinoma: a review of its definition, clinical significance, and comprehensive management. J Oncol. 2022;2022:9567041.

11. Pommergaard HC, Rostved AA, Adam R, et al. European Liver and Intestine Transplant Association (ELITA). vascular invasion and survival after liver transplantation for hepatocellular carcinoma: a study from the european liver transplant registry. HPB (Oxford). 2018;20:768-75.

12. Erstad DJ, Tanabe KK. Prognostic and therapeutic implications of microvascular invasion in hepatocellular carcinoma. Ann Surg Oncol. 2019;26:1474-93.

13. Qin SD, Zhang J, Qi YP, Zhong JH, Xiang BD. Individual and joint influence of cytokeratin 19 and microvascular invasion on the prognosis of patients with hepatocellular carcinoma after hepatectomy. World J Surg Oncol. 2022;20:209.

14. Durnez A, Verslype C, Nevens F, et al. The clinicopathological and prognostic relevance of cytokeratin 7 and 19 expression in hepatocellular carcinoma. A possible progenitor cell origin. Histopathology. 2006;49:138-51.

15. Govaere O, Komuta M, Berkers J, et al. Keratin 19: a key role player in the invasion of human hepatocellular carcinomas. Gut. 2014;63:674-85.

16. Lee JS, Heo J, Libbrecht L, et al. A novel prognostic subtype of human hepatocellular carcinoma derived from hepatic progenitor cells. Nat Med. 2006;12:410-6.

17. Zhuo JY, Lu D, Tan WY, Zheng SS, Shen YQ, Xu X. CK19-positive Hepatocellular carcinoma is a characteristic subtype. J Cancer. 2020;11:5069-77.

18. Kim H, Choi GH, Na DC, et al. Human hepatocellular carcinomas with “Stemness”-related marker expression: keratin 19 expression and a poor prognosis. Hepatology. 2011;54:1707-17.

19. Lee K, Lee KB, Jung HY, et al. The correlation between poor prognosis and increased yes-associated protein 1 expression in keratin 19 expressing hepatocellular carcinomas and cholangiocarcinomas. BMC Cancer. 2017;17:441.

20. Yang XR, Xu Y, Shi GM, et al. Cytokeratin 10 and cytokeratin 19: predictive markers for poor prognosis in hepatocellular carcinoma patients after curative resection. Clin Cancer Res. 2008;14:3850-9.

21. Choi JY, Lee JM, Sirlin CB. CT and MR imaging diagnosis and staging of hepatocellular carcinoma: part I. Development, growth, and spread: key pathologic and imaging aspects. Radiology. 2014;272:635-54.

22. Murakami T, Sofue K, Hori M. Diagnosis of hepatocellular carcinoma using Gd-EOB-DTPA MR imaging. Magn Reson Med Sci. 2022;21:168-81.

23. Huang X, Long L, Wei J, et al. Radiomics for diagnosis of dual-phenotype hepatocellular carcinoma using Gd-EOB-DTPA-enhanced MRI and patient prognosis. J Cancer Res Clin Oncol. 2019;145:2995-3003.

24. Joo I, Lee JM, Lee DH, Jeon JH, Han JK, Choi BI. Noninvasive diagnosis of hepatocellular carcinoma on gadoxetic acid-enhanced MRI: can hypointensity on the hepatobiliary phase be used as an alternative to washout? Eur Radiol. 2015;25:2859-68.

25. Chernyak V, Fowler KJ, Kamaya A, et al. Liver imaging reporting and data system (LI-RADS) version 2018: Imaging of hepatocellular carcinoma in at-risk patients. Radiology. 2018;289:816-30.

26. Qin Q, Deng LP, Chen J, et al. The value of MRI in predicting hepatocellular carcinoma with cytokeratin 19 expression: a systematic review and meta-analysis. Clin Radiol. 2023;78:e975-84.

27. Huang M, Liao B, Xu P, et al. Prediction of microvascular invasion in hepatocellular carcinoma: preoperative Gd-EOB-DTPA-dynamic enhanced MRI and histopathological correlation. Contrast Media Mol Imaging. 2018;2018:9674565.

28. Wang W, Gu D, Wei J, et al. A radiomics-based biomarker for cytokeratin 19 status of hepatocellular carcinoma with gadoxetic acid-enhanced MRI. Eur Radiol. 2020;30:3004-14.

29. Feng ST, Jia Y, Liao B, et al. Preoperative prediction of microvascular invasion in hepatocellular cancer: a radiomics model using Gd-EOB-DTPA-enhanced MRI. Eur Radiol. 2019;29:4648-59.

30. Yip SS, Aerts HJ. Applications and limitations of radiomics. Phys Med Biol. 2016;61:R150-66.

31. Chen Y, Chen J, Zhang Y, et al. Preoperative prediction of cytokeratin 19 expression for hepatocellular carcinoma with deep learning radiomics based on gadoxetic acid-enhanced magnetic resonance imaging. J Hepatocell Carcinoma. 2021;8:795-808.

32. Wang T, Li Z, Yu H, et al. Prediction of microvascular invasion in hepatocellular carcinoma based on preoperative Gd-EOB-DTPA-enhanced MRI: comparison of predictive performance among 2D, 2D-expansion and 3D deep learning models. Front Oncol. 2023;13:987781.

33. Crawshaw M. Multi-task learning with deep neural networks: a survey. ArXiv: 2009.09796, 20206 [Preprint]. 2020 [cited 2025 Apr 23]: [43 p.]. Available from: https://arxiv.org/abs/2009.09796.

34. Zhao Y, Wang X, Che T, Bao G, Li S. Multi-task deep learning for medical image computing and analysis: A review. Comput Biol Med. 2023;153:106496.

35. Caruana R. Multitask Learning. Machine Learning. 1997;28:41-75.

36. Chu T, Zhao C, Zhang J, et al. Application of a convolutional neural network for multitask learning to simultaneously predict microvascular invasion and vessels that encapsulate tumor clusters in hepatocellular carcinoma. Ann Surg Oncol. 2022;29:6774-83.

37. Fan M, Yuan W, Zhao W, et al. Joint prediction of breast cancer histological grade and Ki-67 expression level based on DCE-MRI and DWI radiomics. IEEE J Biomed Health Inform. 2020;24:1632-42.

38. Xu P, Zeng M, Liu K, Shan Y, Xu C, Lin J. Microvascular invasion in small hepatocellular carcinoma: is it predictable with preoperative diffusion-weighted imaging? J Gastroenterol Hepatol. 2014;29:330-6.

39. Cong WM, Bu H, Chen J, et al. Guideline committee. practice guidelines for the pathological diagnosis of primary liver cancer: 2015 update. World J Gastroenterol. 2016;22:9279-87.

40. Zhang X, Li J, Shen F, Lau WY. Significance of presence of microvascular invasion in specimens obtained after surgical treatment of hepatocellular carcinoma. J Gastroenterol Hepatol. 2018;33:347-54.

41. Lee S, Kim SH, Lee JE, Sinn DH, Park CK. Preoperative gadoxetic acid-enhanced MRI for predicting microvascular invasion in patients with single hepatocellular carcinoma. J Hepatol. 2017;67:526-34.

42. Cong WM, Wu MC. New insights into molecular diagnostic pathology of primary liver cancer: Advances and challenges. Cancer Lett. 2015;368:14-9.

43. Kim H, Jang M, Park YN. Histopathological variants of hepatocellular carcinomas: an update according to the 5th edition of the who classification of digestive system tumors. J Liver Cancer. 2020;20:17-24.

44. Zhang H, Wu C, Zhang Z, et al.

45. He K, Zhang X, Ren S, et al.

46. Tan M, Le QV. Efficientnet: rethinking model scaling for convolutional neural networks. arXiv:1905.11946 [Preprint]. 2019: [cited 2025 Apr 23] [11 p.]. Available from: https://doi.org/10.48550/arXiv.1905.11946.

47. Caruana R, Sa VRD.

48. Misra I, Shrivastava A, Gupta A, et al.

49. Jaderberg M, Simonyan K, Zisserman A, et al. Spatial transformer networks. arXiv:1506.02025v3 [Preprint]. 2016: [cited 2025 Apr 23] [15 p]. Available from: https://doi.org/10.48550/arXiv.1506.02025.

50. Santoro A, Raposo D, Barrett DGT, et al. A simple neural network module for relational reasoning. arXiv:1706.01427v1 [Preprint]. 2017: [cited 2025 Apr 23] [16 p] Available form: https://doi.org/10.48550/arXiv.1706.01427.

51. Yang F, Wan Y, Xu L, et al. MRI-radiomics prediction for cytokeratin 19-positive hepatocellular carcinoma: a multicenter study. Front Oncol. 2021;11:672126.

52. Hervella ÁS, Rouco J, Novo J, Ortega M. Multi-adaptive optimization for multi-task learning with deep neural networks. Neural Netw. 2024;170:254-65.

53. Zhang Y, Lv X, Qiu J, et al. Deep learning with 3D convolutional neural network for noninvasive prediction of microvascular invasion in hepatocellular carcinoma. J Magn Reson Imaging. 2021;54:134-43.

54. Sun BY, Gu PY, Guan RY, et al. Deep-learning-based analysis of preoperative MRI predicts microvascular invasion and outcome in hepatocellular carcinoma. World J Surg Oncol. 2022;20:189.